Calidi Biotherapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $2.7M
- Price
- $0.1456
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.46%
- Volume
- 1.0M
Quote data as of 5:17 AM ET
About
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.
Quick stats
Shares outstanding19.3M
Computed float14.5M
Float sourceUnknown
Cash runway (months)1.2
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001855485
Websitehttps://calidibio.com
AI Summary
AI-generated23d agomajorbullishregulatoryCalidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
Calidi Biotherapeutics received positive pre-IND feedback from the FDA for its lead candidate CLD-401, agreeing on the IND-enabling preclinical plans and clinical strategy.
The company is targeting a regulatory submission by year-end 2026 and plans to initiate the first-in-human clinical trial in early 2027.
This milestone validates the proprietary RedTail platform, which focuses on systemic delivery of oncolytic viruses for metastatic sites.